– February 1, 2013
February 1, 2013
View Issues
-
Compliance with Recommended Adjuvant Chemotherapy for Rectal Cancer: Room for Improvement
In examining the National Comprehensive Cancer Network Colorectal Database, reasons for not completing the recommended postsurgical chemotherapy were examined. Although only 17% of patients for whom adjuvant therapy was recommended failed to receive treatment, the decision to not proceed was based on a number of factors, most notably the existence of comorbidities. In comparison to this cohort of patients treated at academic centers, the percent of patients not treated with adjuvant chemotherapy is likely to be greater in the community setting. -
10 Years of Adjuvant Tamoxifen Better Than 5
Ten years of adjuvant tamoxifen is significantly better than the standard 5 years of treatment. Continuing adjuvant tamoxifen for 10 years substantially reduces rates of both recurrence and breast cancer-specific mortality in women with estrogen receptor-positive breast cancer. -
HIV-Related Anal Cancer: Incidence Rising Despite Effective Antiretroviral Treatment
Relative to the general population, the risk of anal cancer in HIV-infected patients remains very high. Unlike other malignancies associated with AIDS, effective antiretroviral treatment appears to have no preventive effect on anal cancer, particularly among men who have sex with men. -
Arsenic as a Single Agent for Elderly APL Patients
The experience from Harbin, China, in the treatment of de novo acute promyelocytic leukemia (APL) in patients 60 years and older demonstrates the efficacy and safety of single agent arsenic trioxide. This agent with or without all trans retinoic acid may ultimately prove optimal for induction and maintenance APL treatment in older adults. -
Repurposing an Old Drug for Cancer Control: What Does Metformin Bring to the Plate?
Metformin use was associated with better disease-specific survival in women who developed ovarian cancer. The data support (preclinical observations of) the anticancer activity of metformin in several solid tumors and provide rationale for planned and ongoing clinical trials. -
Pharmacology Watch: FDA Approves Apixaban for Patients with Nonvalvular AF
Apixaban approval; new dental clinical practice guideline; apixaban for VTE; aspirin resistance; tamoxifen treatment; and FDA actions. -
Clinical Briefs in Primary Care Supplement